Fig. 2From: Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphomaThe distinct and complementary mechanisms of ibrutinib and venetoclax make the combination rational in CLL/SLL. CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; LN, lymph node; PB, peripheral blood; MOMP, mitochondrial outer membrane permeabilizationBack to article page